How to bid on a FACSLyric Flow Cytometry System for the National Cancer Institute

What the agency is buying

The National Cancer Institute (NCI) is looking to acquire a BD FACSLyric flow cytometry system. This includes the proprietary hardware, firmware, software, quality assurance materials, installation, training, warranty, and ongoing support. The NCI intends to purchase this system directly from Becton, Dickinson and Company (BD) due to its unique specifications and integrated platform design.

Key dates and deadlines

This Request for Information (RFI) was published on July 29, 2026. If you wish to submit a capability statement, it must be received by 9:00 a.m. EDT on August 7, 2026. The NCI expects to make an award approximately five calendar days after this closing date, unless a competitive procurement is deemed necessary based on responses.

Who this opportunity suits

This opportunity is primarily for businesses, including small and disadvantaged businesses, that believe they can provide an equivalent BD FACSLyric flow cytometry system or demonstrate the ability to meet the NCI's specific requirements. The NCI has stated that the system's proprietary components and integrated nature make it a sole-source acquisition, but they are open to reviewing capability statements from other responsible sources.

How to respond

To access the original solicitation details, click “View original source” above. If the first click takes you to the portal’s homepage, click it again to go directly to the bid. You may need a free account to view any associated documents. Capability statements must be submitted via email to [email protected] by the deadline of August 7, 2026, at 9:00 a.m. EDT.

Tips for preparing a competitive response

Even though this is a sole-source justification, a well-crafted capability statement can still be valuable. Clearly articulate how your firm can meet all aspects of the NCI's requirement, specifically addressing the proprietary hardware, firmware, software, quality assurance, installation, training, warranty, and support. Focus on demonstrating that your proposed solution is truly equivalent and can integrate seamlessly without requiring significant changes to NCI's existing workflows or introducing technical risks.

Ensure your statement highlights any relevant past performance with similar complex equipment or scientific instrumentation. Detail your firm's experience with government contracts and any applicable small business certifications. Your response should be concise, professional, and directly address the agency's stated needs and concerns about substitution.